Recent Updates
Recently added Catalysts
IDYA Positive Sentiment

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

Key Takeaway: IDEAYA Biosciences, Inc. announced its participation in the Stifel Virtual Targeted Oncology Forum on April 16, 2024. CEO Yujiro S. Hata will engage in a fireside chat hosted by Benjamin Burnett, Ph.D. The event will be accessible via a live audio webcast, with a replay available for 30 days. IDEAYA focuses on precision medicine and targeted therapeutics.
Price reaction · baseline $43.88 (2024-03-28 close) · clean, no other IDYA news in the window
day 0 close · peak
-3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant investor relations event.
  • Opportunity for CEO to engage with investors.
  • Focus on precision medicine and targeted therapeutics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma

Full Press Release Details

SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA ), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
Stifel Virtual Targeted Oncology Forum Tuesday, April 16 th , 2024 at 12:00 PM ET
• Fireside chat with Yujiro S. Hata , Chief Executive Officer, hosted by Benjamin Burnett , Ph.D., Managing Director, Equity Analyst
A live audio webcast of conference event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
IDEAYA Biosciences Andres Ruiz Briseno Senior Vice President, Head of Finance and Investor Relations [email protected]

Frequently Asked Questions

When is the IDEAYA investor relations event?

The event is scheduled for April 16, 2024, at 12:00 PM ET.

Who will be speaking at the investor event?

CEO Yujiro S. Hata will participate in a fireside chat.

How can I access the event?

The event will be available via a live audio webcast on IDEAYA's website.

What is IDEAYA's focus in oncology?

IDEAYA specializes in precision medicine and targeted therapeutics.

Last updated: Apr 1, 2024